{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:55:29Z","timestamp":1782863729258,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111845","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:05:54Z","timestamp":1782860754000},"source":"Crossref","is-referenced-by-count":0,"title":["Population-Level Survival Trends in Hematologic Malignancies: A Surveillance, Epidemiology, and End Results (SEER) Analysis of 494,244 Patients From 2000 to 2020"],"prefix":"10.7759","author":[{"given":"Kevin","family":"Woodson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026, 76:e70043. 10.3322\/caac.70043","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel U","year":"2022","unstructured":"Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022, 97:S3-25. 10.1002\/ajh.26512","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma","volume":"59","author":"Molina A","year":"2008","unstructured":"Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008, 59:237-50. 10.1146\/annurev.med.59.060906.220345","journal-title":"Annu Rev Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang ML","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al.. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013, 369:507-16. 10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi F","year":"2010","unstructured":"Ravandi F, O'Brien S, Thomas D, et al.. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010, 116:2070-7. 10.1182\/blood-2009-12-261586","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy VH","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004, 291:2720-6. 10.1001\/jama.291.22.2720","journal-title":"JAMA"},{"key":"ref9","unstructured":"SEER is an authoritative source for cancer statistics in the United States. (2025). Accessed. April 12, 2026: http:\/\/seer.cancer.gov."},{"key":"ref10","unstructured":"SEER Cancer Statistics Review (CSR) 1975-2018. (2021). Accessed. April 12, 2026: https:\/\/seer.cancer.gov\/csr\/1975_2018\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte D","year":"2009","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009, 113:1408-11. 10.1182\/blood-2008-06-164863","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.942122","article-title":"Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method","volume":"12","author":"Xie S","year":"2022","unstructured":"Xie S, Yu Z, Feng A, Zheng S, Li Y, Zeng Y, Lyu J. Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method. Front Oncol. 2022, 12:942122. 10.3389\/fonc.2022.942122","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores GM","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012, 119:34-43. 10.1182\/blood-2011-04-347872","journal-title":"Blood"},{"key":"ref14","unstructured":"SEER*Stat Software. (2026). Accessed. April 12, 2026: http:\/\/seer.cancer.gov\/seerstat."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-1001-7","article-title":"Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort","volume":"34","author":"Chen Y","year":"2017","unstructured":"Chen Y, Lairson DR, Chan W, Du XL. Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. Med Oncol. 2017, 34:153. 10.1007\/s12032-017-1001-7","journal-title":"Med Oncol"},{"key":"ref16","article-title":"Analyzing survival trends in multiple myeloma patients in pre and post-bortezomib era using the SEER database","volume":"124","author":"Umakanthan JM","year":"2014","unstructured":"Umakanthan JM, Uprety D, Kasireddy V. Analyzing survival trends in multiple myeloma patients in pre and post-bortezomib era using the SEER database. Blood. 2014, 124:2639.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran B","year":"2012","unstructured":"Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012, 97:1916-24. 10.3324\/haematol.2012.066100","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102549","article-title":"Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019","volume":"71","author":"Linet MS","year":"2024","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019. EClinicalMedicine. 2024, 71:102549. 10.1016\/j.eclinm.2024.102549","journal-title":"EClinicalMedicine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014127","article-title":"Evolving racial\/ethnic disparities in AML survival in the novel therapy era","volume":"9","author":"Wang X","year":"2025","unstructured":"Wang X, Gimotty PA, Matthews AH, et al.. Evolving racial\/ethnic disparities in AML survival in the novel therapy era. Blood Adv. 2025, 9:533-44. 10.1182\/bloodadvances.2024014127","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100070","article-title":"Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis","volume":"2","author":"Loeb N","year":"2025","unstructured":"Loeb N, Katsnelson O, Jain A, Tahvildar P, Teitelbaum D, Garcia-Horton A. Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis. Blood Neoplasia. 2025, 2:100070. 10.1016\/j.bneo.2025.100070","journal-title":"Blood Neoplasia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20087","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"Flowers CR","year":"2010","unstructured":"Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010, 60:393-408. 10.3322\/caac.20087","journal-title":"CA Cancer J Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman AJ","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS, et al.. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010, 116:5501-6. 10.1182\/blood-2010-07-298760","journal-title":"Blood"},{"key":"ref23","unstructured":"SEER cancer stat facts. acute myeloid leukemia. (2026). Accessed: April 12, 2026: http:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507867-population-level-survival-trends-in-hematologic-malignancies-a-surveillance-epidemiology-and-end-results-seer-analysis-of-494244-patients-from-2000-to-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:06:01Z","timestamp":1782860761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507867-population-level-survival-trends-in-hematologic-malignancies-a-surveillance-epidemiology-and-end-results-seer-analysis-of-494244-patients-from-2000-to-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.111845","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}